Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
1/2/25 Neumora Therapeutics (NMRA) Navacaprant for Major Depressive Disorder (MDD) Subscribers Only Subscribers Only Subscribers Only
12/20/24 Lexicon Pharmaceuticals (LXRX) Inpefa for Diabetes Mellitus, Type I Subscribers Only Subscribers Only Subscribers Only
12/20/24 GSK (GSK) Zejula for Ovarian Cancer Subscribers Only Subscribers Only Subscribers Only
12/20/24 GSK (GSK) Jemperli for Ovarian Cancer Subscribers Only Subscribers Only Subscribers Only
12/20/24 Novo Nordisk (NVO) CagriSema for Obesity Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
03/25/2024 Subscribers Only Subscribers Only Regulatory - Response to Complete Response Letter
06/30/2024 Subscribers Only Subscribers Only Trial Announcement - Trial Completion (Emerging Markets)
09/12/2024 Subscribers Only Subscribers Only Company - Analyst/R&D Update
09/30/2024 Subscribers Only Subscribers Only Trial Data - Updated Results
10/16/2024 Subscribers Only Subscribers Only Company - Analyst/R&D Update